<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03818269</url>
  </required_header>
  <id_info>
    <org_study_id>DARGENT 2018</org_study_id>
    <nct_id>NCT03818269</nct_id>
  </id_info>
  <brief_title>Study of Subcutaneous Interstitial Pressure During Sepsis</brief_title>
  <acronym>PISEP</acronym>
  <official_title>Study of Subcutaneous Interstitial Pressure During Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology of sepsis is characterized by the sudden onset of vasodilation and&#xD;
      vascular permeability with capillary leakage. This leakage contributes to the development of&#xD;
      generalized edema which is not clinically detectable below 4 litres but which becomes visible&#xD;
      after a few days. The edema accumulates mainly at the subcutaneous level due to the high&#xD;
      compliance of this tissue. Edema, and therefore hydrosodium overload, testifies to the&#xD;
      severity of the inflammation. However, it could also be harmful in itself (affecting&#xD;
      microcirculation and increasing mortality) as suggested by numerous clinical and experimental&#xD;
      studies.&#xD;
&#xD;
      The transfer of fluids between vascular and interstitial compartments during sepsis therefore&#xD;
      has a central role in the pathophysiology of the disease and associated mortality. These&#xD;
      transfers are mainly controlled at the microvascular level (with constant permeability) by&#xD;
      the difference between capillary (CP) and interstitial (IP) pressures. In healthy subjects,&#xD;
      subcutaneous IP is discreetly negative (-1 mmHg) and varies very little. On the other hand, a&#xD;
      sometimes drastic decrease in IP has been described in various localized and systemic&#xD;
      inflammatory situations. These pressure variations may be explained by the collagen structure&#xD;
      of the interstitial tissue and a change in the three-dimensional conformation of these&#xD;
      macromolecules induced by inflammation mediators. In an animal model of sepsis, a study&#xD;
      showed significantly lower pressure in a group of animals in endotoxic shock. IP has never&#xD;
      been measured in humans during sepsis. The objective of this study is to analyze subcutaneous&#xD;
      IP (SCIP) in patients with septic shock compared with controls in order to evaluate the&#xD;
      direct role of interstitial tissue in the onset of edema during sepsis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Value of Initial subcutaneous interstitial pressure</measure>
    <time_frame>Day 0</time_frame>
    <description>Measure the difference between the subcutaneous interstitial pressure of patients in septic shock compared to patients without sepsis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Patients With Septic Shock</condition>
  <arm_group>
    <arm_group_label>Septic shock</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subcutaneous pressure measurement</intervention_name>
    <description>Subcutaneous interstitial measurement at D1 and D2</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Septic shock</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria common to both groups:&#xD;
&#xD;
          -  Adult,&#xD;
&#xD;
          -  Admitted within the last 24 hours in intensive care,&#xD;
&#xD;
          -  Under mechanical ventilation with orotracheal intubation,&#xD;
&#xD;
          -  Without clinically detectable edema (in any area)&#xD;
&#xD;
          -  Patient and/or guardian and/or close relative has given written consent&#xD;
&#xD;
        Patients included in the &quot;septic shock&quot; arm:&#xD;
&#xD;
          -  Diagnosis of septic shock as defined by the &quot;Sepsis-3&quot; Consensus Conference (JAMA&#xD;
             2016) (34): documented or highly suspected infection with SOFA ≥ 2, persistent&#xD;
             hypotension after correction of hypovolemia requiring vasopressor administration, and&#xD;
             serum lactate &gt; 2 mmol/l.&#xD;
&#xD;
          -  Vascular filling &lt; 50 ml/kg&#xD;
&#xD;
        Patients included in the control arm:&#xD;
&#xD;
          -  Absence of sepsis and shock from any cause:&#xD;
&#xD;
               -  PAS &gt; 100 mmHg&#xD;
&#xD;
               -  Absence of vasopressors&#xD;
&#xD;
               -  Preserved urine &gt; 0.5 ml/kg/h&#xD;
&#xD;
               -  Normal serum lactate&#xD;
&#xD;
          -  Crystalloid infusions &lt; 50ml/kg over the previous 12 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not affiliated to national health insurance&#xD;
&#xD;
          -  under court protection&#xD;
&#xD;
          -  pregnant or breastfeeding&#xD;
&#xD;
          -  Clinical disseminated intravascular coagulation (DIC) with hemorrhagic syndrome&#xD;
&#xD;
          -  Admitted after resuscitation for cardiac arrest&#xD;
&#xD;
          -  Presenting cardiogenic shock&#xD;
&#xD;
          -  Presenting acute pancreatitis&#xD;
&#xD;
          -  Severe overall dehydration (clinical signs of dehydration and natremia &gt; 150mmol/l)&#xD;
&#xD;
          -  Presenting metformin intoxication&#xD;
&#xD;
          -  In severe sepsis or septic shock for more than 24 hours,&#xD;
&#xD;
          -  Dying or for whom death seems imminent (within 24 hours),&#xD;
&#xD;
          -  Hypersensitivity to lidocaine and/or prilocaine or local anesthetics of the amide type&#xD;
             or to any of the excipients of EMLAPATCH®&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Auguste DARGENT</last_name>
    <phone>+33 3.80.29.37.51</phone>
    <email>auguste.dargent@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Auguste DARGENT</last_name>
      <phone>03 80 29 37 51</phone>
      <phone_ext>+33</phone_ext>
      <email>auguste.dargent@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DARGENT Auguste</last_name>
      <phone>0472112862</phone>
      <email>auguste.dargent@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

